Table 2 Observed sustained virological response rates at 4 weeks (SVR4) and at 12 weeks (SVR12) after completing therapy with daclatasvir and sofosbuvir, with or without ribavirin
Observed | SVR4 | SVR12 | ||||||
|---|---|---|---|---|---|---|---|---|
As-treated | Intent-to-treat | As-treated | Intent-to-treat | |||||
Country | % | Fraction | % | Fraction | % | Fraction | % | Fraction |
Austria | 100 | 14/14 | 100 | 14/14 | 100 | 13/13 | 93 | 13/14 |
Denmark | 94 | 17/18 | 89 | 17/19 | 100 | 17/17 | 89 | 17/19 |
Spain | 99 | 141/142 | 94 | 141/150 | 99 | 138/140 | 92 | 138/150 |
Sweden | 100 | 15/15 | 94 | 15/16 | 100 | 15/15 | 94 | 15/16 |
Switzerland | 85 | 23/27 | 82 | 23/28 | 85 | 22/26 | 85 | 22/26 |
UK | 100 | 14/14 | 82 | 14/17 | 100 | 14/14 | 82 | 14/17 |
Overall | 97 | 224/230 | 92 | 224/244 | 97 | 219/225 | 90 | 219/242 |